Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Locally Advanced and/or Metastatic Endometrial Cancer
NCT00030485Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2002
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in endometrial cancer (EC), sponsored by National Cancer Institute. Started Jan 2002; status: completed.
02
Drugs
erlotinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00030485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030485.